High prescription drug prices, which have garnered attention across the political spectrum, often make access to essential medicines quite difficult for patients. Although lowering prescription drug prices is a bipartisan objective, the role of antitrust law in restoring competition and restraining price increases is not well understood by policy makers or the public.
In this Viewpoint, we explore 3 recent legal antitrust cases in which aggrieved competitors sued rival manufacturers, alleging that the anticompetitive practices of exclusive dealing and bundling prevented their products from gaining a foothold in the pharmaceutical marketplace.
Sinha MS, Curfman GD, Carrier MA. Antitrust, Market Exclusivity, and Transparency in the Pharmaceutical Industry. JAMA. 2018;319(22):2271–2272. doi:10.1001/jama.2018.3478
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: